Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
TXG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.78 - $29.37
Previous CloseN/A
Volume385.49K
Average Volume (3M)3.32M
Market Cap
$926.99M
Enterprise Value$1.44B
Total Cash (Recent Filing)-$47.86M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.70
Next Earnings
May 08, 2025EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding109,376,915
10 Day Avg. Volume4,031,620
30 Day Avg. Volume3,319,852
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.08
Price to Cash Flow (P/CF)-47.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.46
Enterprise Value/Ebitda-10.71
Forecast
1Y Price Target
$15.73Price Target Upside104.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Product InnovationTXG announced new plate workflows to increase throughput on Chromium X and iX instruments, allowing for up to 700+ samples per run and offering flexibility in workflow design.
Revenue PerformanceRevenues beat expectations with a 9% increase, indicating strong performance.
Technological AdvancementThe upcoming Visium HD 3' assay will provide researchers with higher sensitivity and resolution without the need for added tissue optimization.
Bears Say
Funding ChallengesTXG's business has significant exposure to the academic end-market, especially in the U.S., which poses a risk due to recent funding cuts.
Market CompetitionThe ongoing reorganization of TXG's sales force coincides with the introduction of lower-priced competition, adding further challenges.
Regulatory ImpactThe recently implemented NIH indirect costs cap is impacting researchers' behavior, leading to reduced spending on instruments.
---
Ownership Overview
2.72% Insiders
24.88% Mutual Funds
1.83% Other Institutional Investors
45.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TXG FAQ
What was 10x Genomics Inc’s price range in the past 12 months?
10x Genomics Inc lowest stock price was $6.78 and its highest was $29.37 in the past 12 months.
What is 10x Genomics Inc’s market cap?
10x Genomics Inc’s market cap is $926.99M.
When is 10x Genomics Inc’s upcoming earnings report date?
10x Genomics Inc’s upcoming earnings report date is May 08, 2025 which is in 16 days.
How were 10x Genomics Inc’s earnings last quarter?
10x Genomics Inc released its earnings results on Feb 12, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.299 by -$0.101.
Is 10x Genomics Inc overvalued?
According to Wall Street analysts 10x Genomics Inc’s price is currently Undervalued.
Does 10x Genomics Inc pay dividends?
10x Genomics Inc does not currently pay dividends.
What is 10x Genomics Inc’s EPS estimate?
10x Genomics Inc’s EPS estimate is -0.47.
How many shares outstanding does 10x Genomics Inc have?
10x Genomics Inc has 109,376,915 shares outstanding.
What happened to 10x Genomics Inc’s price movement after its last earnings report?
10x Genomics Inc reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.299. Following the earnings report the stock price went down -0.5%.
Which hedge fund is a major shareholder of 10x Genomics Inc?
Currently, no hedge funds are holding shares in TXG
---
10x Genomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.73 (104.82% Upside)
$15.73 (104.82% Upside)
Blogger Sentiment
Bearish
TXG Sentiment 67%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 4.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $338.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.24%
12-Months-Change
Fundamentals
Return on Equity
-25.17%
Trailing 12-Months
Asset Growth
-4.82%
Trailing 12-Months
Company Description
10x Genomics Inc
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
---
TXG Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While the company experienced significant product innovation and customer adoption, challenges such as revenue decline, market uncertainties, and reduced funding from key stakeholders like NIH have created a cautious outlook. The highlights are balanced by substantial lowlights, leading to an overall neutral sentiment.Read More>---
TXG Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China
---
TXG Stock 12 Month Forecast
Average Price Target
$15.73
▲(104.82% Upside)
Technical Analysis
Best Analysts Covering TXG
1 Year
1 Year Success Rate
6/16 ratings generated profit
1 Year Average Return
-23.08%
reiterated a buy rating 2 months ago
Copying Tejas Savant's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -23.08% per trade.
---